{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T14:57:59Z","timestamp":1787497079780,"version":"build-2736575974"},"reference-count":66,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","japha.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Pharmacists Association"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.japh.2020.09.013","type":"journal-article","created":{"date-parts":[[2020,10,27]],"date-time":"2020-10-27T18:56:21Z","timestamp":1603824981000},"page":"e20-e44","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Effects of hydrocodone rescheduling on opioid use outcomes: A systematic review"],"prefix":"10.1016","volume":"61","author":[{"given":"Silken A.","family":"Usmani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7590-3683","authenticated-orcid":false,"given":"Josef","family":"Hollmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amie","family":"Goodin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan M.","family":"Hincapie-Castillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0914-2086","authenticated-orcid":false,"given":"Lauren E.","family":"Adkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1036-0371","authenticated-orcid":false,"given":"Natalie","family":"Ourhaan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Razanne","family":"Oueini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3366-9678","authenticated-orcid":false,"given":"Hemita","family":"Bhagwandass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6086-030X","authenticated-orcid":false,"given":"Taylor","family":"Easey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott Martin","family":"Vouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5152","key":"10.1016\/j.japh.2020.09.013_bib1","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.15585\/mmwr.mm675152e1","article-title":"Drug and opioid-involved overdose deaths \u2013 United States, 2013-2017","volume":"67","author":"Scholl","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"163","key":"10.1016\/j.japh.2020.09.013_bib2","first-page":"49661","article-title":"Schedules of controlled substances: rescheduling of hydrocodone combination products from schedule III to schedule II. Final rule","volume":"79","year":"2014","journal-title":"Fed Regist"},{"key":"10.1016\/j.japh.2020.09.013_bib3","unstructured":"21 United States Code (USC) Controlled Substances Act. Drug Enforcement Administration. Available at: https:\/\/www.deadiversion.usdoj.gov\/21cfr\/21usc\/. Accessed August 5, 2020."},{"key":"10.1016\/j.japh.2020.09.013_bib4","author":"Higgins"},{"issue":"1","key":"10.1016\/j.japh.2020.09.013_bib5","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1186\/s13643-019-1188-0","article-title":"How should systematic reviewers handle conference abstracts? A view from the trenches","volume":"8","author":"Scherer","year":"2019","journal-title":"Syst Rev"},{"key":"10.1016\/j.japh.2020.09.013_bib6","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"issue":"24","key":"10.1016\/j.japh.2020.09.013_bib7","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.2146\/ajhp160548","article-title":"Evaluation of opioid prescribing after rescheduling of hydrocodone-containing products","volume":"74","author":"Bernhardt","year":"2017","journal-title":"Am J Health Syst Pharm"},{"issue":"9","key":"10.1016\/j.japh.2020.09.013_bib8","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1002\/pds.4249","article-title":"Patterns of abuse and routes of administration for immediate-release hydrocodone combination products","volume":"26","author":"Cassidy","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"10.1016\/j.japh.2020.09.013_bib9","doi-asserted-by":"crossref","first-page":"e20171765","DOI":"10.1542\/peds.2017-1765","article-title":"Effect of FDA Investigation on opioid prescribing to children after tonsillectomy\/adenoidectomy","volume":"140","author":"Chua","year":"2017","journal-title":"Pediatrics"},{"issue":"4","key":"10.1016\/j.japh.2020.09.013_bib10","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.jemermed.2016.08.026","article-title":"Decreased opioid prescribing in a pediatric Emergency Department after the rescheduling of hydrocodone","volume":"52","author":"Chumpitazi","year":"2017","journal-title":"J Emerg Med"},{"issue":"4","key":"10.1016\/j.japh.2020.09.013_bib11","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s13181-017-0622-8","article-title":"Evaluation of a Food and Drug Administration mandate to limit acetaminophen in prescription combination products","volume":"13","author":"Goldberger","year":"2017","journal-title":"J Med Toxicol"},{"issue":"4","key":"10.1016\/j.japh.2020.09.013_bib12","doi-asserted-by":"crossref","first-page":"396","DOI":"10.5811\/westjem.2016.5.29924","article-title":"The decline in hydrocodone\/acetaminophen prescriptions in emergency departments in the Veterans Health Administration between 2009 to 2015","volume":"17","author":"Grasso","year":"2016","journal-title":"West J Emerg Med"},{"issue":"2","key":"10.1016\/j.japh.2020.09.013_bib13","doi-asserted-by":"crossref","first-page":"77","DOI":"10.5055\/jom.2017.0371","article-title":"Opioid pain medication prescriptions obtained through emergency medical visits in the Veterans Health Administration","volume":"13","author":"Grasso","year":"2017","journal-title":"J Opioid Manag"},{"issue":"12","key":"10.1016\/j.japh.2020.09.013_bib14","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1001\/jamasurg.2018.2651","article-title":"Association of hydrocodone schedule change with opioid prescriptions following surgery [published correction appears in JAMA Surg. 2018;153(12):1164]","volume":"153","author":"Habbouche","year":"2018","journal-title":"JAMA Surg"},{"key":"10.1016\/j.japh.2020.09.013_bib15","first-page":"427","article-title":"Opioid prescriptions in older Medicare beneficiaries following the 2014 hydrocodone rescheduling","volume":"27","author":"Kuo","year":"2018","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"10.1016\/j.japh.2020.09.013_bib16","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/pds.4639","article-title":"Using trajectory models to assess the effect of hydrocodone upscheduling among chronic hydrocodone users","volume":"28","author":"Murimi","year":"2019","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"3","key":"10.1016\/j.japh.2020.09.013_bib17","doi-asserted-by":"crossref","first-page":"362","DOI":"10.3122\/jabfm.2019.03.180356","article-title":"The impact of increased hydrocodone regulation on opioid prescribing in an urban Safety-Net Health Care System","volume":"32","author":"Northrup","year":"2019","journal-title":"J Am Board Fam Med"},{"issue":"12","key":"10.1016\/j.japh.2020.09.013_bib18","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1016\/j.ajem.2016.09.002","article-title":"Has the rescheduling of hydrocodone changed ED prescribing practices?","volume":"34","author":"Oehler","year":"2016","journal-title":"Am J Emerg Med"},{"issue":"5","key":"10.1016\/j.japh.2020.09.013_bib19","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/pds.4376","article-title":"Decline in opioid prescribing after federal rescheduling of hydrocodone products","volume":"27","author":"Raji","year":"2018","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"10.1016\/j.japh.2020.09.013_bib20","first-page":"457","article-title":"Surveillance of hydrocodone overdoses using a National real-time data system","volume":"57","author":"Rege","year":"2019","journal-title":"Clin Toxicol"},{"issue":"4","key":"10.1016\/j.japh.2020.09.013_bib21","doi-asserted-by":"crossref","first-page":"e027117","DOI":"10.1136\/bmjopen-2018-027117","article-title":"Descriptive, observational study of pharmaceutical and non-pharmaceutical arrests, use, and overdoses in Maine","volume":"9","author":"Simpson","year":"2019","journal-title":"BMJ Open"},{"issue":"4","key":"10.1016\/j.japh.2020.09.013_bib22","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.surg.2018.06.018","article-title":"Postoperative opioid prescribing practices and the impact of the hydrocodone schedule change","volume":"164","author":"Tan","year":"2018","journal-title":"Surgery"},{"key":"10.1016\/j.japh.2020.09.013_bib23","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.addbeh.2017.08.005","article-title":"Trends in average days' supply of opioid medications in Medicaid and commercial insurance","volume":"76","author":"Tehrani","year":"2018","journal-title":"Addict Behav"},{"issue":"5","key":"10.1016\/j.japh.2020.09.013_bib24","first-page":"532","article-title":"The effect of a federal controlled substance act schedule change on hydrocodone combination products claims in a Medicaid population","volume":"23","author":"Tran","year":"2017","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.japh.2020.09.013_bib25","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1016\/j.jval.2018.04.033","article-title":"Annual change in controlled substance opioid prescribing and concomitant medications from an urban academic emergency department from 2011 \u2013 2016","volume":"21","author":"Voelker","year":"2018","journal-title":"Value Health"},{"issue":"suppl22","key":"10.1016\/j.japh.2020.09.013_bib26","article-title":"Opioid prescriptions by emergency physicians in Ohio, 2010 to 2014","volume":"23","author":"Weiner","year":"2016","journal-title":"Acad Emerg Med"},{"issue":"12","key":"10.1016\/j.japh.2020.09.013_bib27","doi-asserted-by":"crossref","first-page":"e972","DOI":"10.1200\/JOP.2017.024901","article-title":"Opioid prescription trends among patients with cancer referred to outpatient palliative care over a 6-year period","volume":"13","author":"Haider","year":"2017","journal-title":"J Oncol Pract"},{"issue":"Suppl 2","key":"10.1016\/j.japh.2020.09.013_bib28","first-page":"326","article-title":"Impact of hydrocodone schedule change on patients undergoing mastectomy","volume":"24","author":"Pryor","year":"2017","journal-title":"Ann Surg Oncol"},{"issue":"2S","key":"10.1016\/j.japh.2020.09.013_bib29","doi-asserted-by":"crossref","first-page":"S78","DOI":"10.1016\/j.japh.2017.01.010","article-title":"The impact of pharmacy services on opioid prescribing in dental practice","volume":"57","author":"Stewart","year":"2017","journal-title":"J Am Pharm Assoc (2003)"},{"issue":"10","key":"10.1016\/j.japh.2020.09.013_bib30","first-page":"1019","article-title":"Tramadol misuse and abuse: a six year retrospective cohort study assessing severity of exposure outcomes in relation to the rescheduling of hydrocodone in Texas","volume":"56","author":"Weiss","year":"2018","journal-title":"Clin Toxicol"},{"key":"10.1016\/j.japh.2020.09.013_bib31","doi-asserted-by":"crossref","first-page":"S372","DOI":"10.1016\/j.jval.2018.09.2220","article-title":"Trends in opioid prescribing in primary care physician offices in the united states: 2006-2015","volume":"21","author":"Alsheikh","year":"2018","journal-title":"Value Health"},{"issue":"8","key":"10.1016\/j.japh.2020.09.013_bib32","first-page":"709","article-title":"Intentional abuse cases mentioning prescription opioid products following the hydrocodone rescheduling","volume":"54","author":"Fischer","year":"2016","journal-title":"Clin Toxicol"},{"issue":"4","key":"10.1016\/j.japh.2020.09.013_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.jamcollsurg.2017.07.175","article-title":"Effect of opioid schedule change on prescribing habits of surgeons","volume":"225","author":"Habbouche","year":"2017","journal-title":"J Am Coll Surg"},{"issue":"11","key":"10.1016\/j.japh.2020.09.013_bib34","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1080\/15563650.2019.1574976","article-title":"The effect of a more strict 2014 DEA schedule designation for hydrocodone products on opioid prescription rates in the United States","volume":"57","author":"Harrison","year":"2019","journal-title":"Clin Toxicol (Phila)"},{"issue":"3","key":"10.1016\/j.japh.2020.09.013_bib35","doi-asserted-by":"crossref","first-page":"A255","DOI":"10.1016\/j.jval.2016.03.1020","article-title":"Rescheduling hydrocodone combination products: assessing the impact on opioid utilization","volume":"19","author":"Hatfield","year":"2016","journal-title":"Value Health"},{"issue":"5","key":"10.1016\/j.japh.2020.09.013_bib36","first-page":"A230","article-title":"Assessing the impact of hydrocodone rescheduling on opioid prescribing using prescription monitoring program data","volume":"20","author":"Hatfield","year":"2017","journal-title":"Value Health"},{"issue":"5","key":"10.1016\/j.japh.2020.09.013_bib37","doi-asserted-by":"crossref","first-page":"434","DOI":"10.3109\/15563650.2016.1148720","article-title":"Trends in analgesic exposures reported to Texas Poison Centers following increased regulation of hydrocodone","volume":"54","author":"Haynes","year":"2016","journal-title":"Clin Toxicol (Phila)"},{"issue":"9","key":"10.1016\/j.japh.2020.09.013_bib38","first-page":"1","article-title":"Drugs most frequently involved in drug overdose deaths: United States, 2011\u20132016","volume":"67","author":"Hedegaard","year":"2018","journal-title":"Natl Vital Stat Rep"},{"key":"10.1016\/j.japh.2020.09.013_bib39","first-page":"S83","article-title":"Assessment of opioid prescribing trends related to the hydrocodone class rescheduling","volume":"21","author":"Heiney","year":"2015","journal-title":"J Manag Care Spec Pharm"},{"issue":"3","key":"10.1016\/j.japh.2020.09.013_bib40","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1001\/jamainternmed.2015.7799","article-title":"Effect of US drug enforcement administration's rescheduling of hydrocodone combination analgesic productson opioid analgesic prescribing","volume":"176","author":"Jones","year":"2016","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.japh.2020.09.013_bib41","first-page":"328","article-title":"Opioid analgesic utilization, poisonings and deaths: the impact of hydrocodone rescheduling","volume":"27","author":"Karami","year":"2018","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"10","key":"10.1016\/j.japh.2020.09.013_bib42","first-page":"449","article-title":"Impact of the hydrocodone schedule change on opioid prescription patterns in South Dakota","volume":"70","author":"Kuschel","year":"2017","journal-title":"S D Med"},{"issue":"3","key":"10.1016\/j.japh.2020.09.013_bib43","first-page":"601","article-title":"Retrospective review of prescription practice changes due to rescheduling hydrocodone in an academic practice: an update","volume":"20","author":"Ngo","year":"2019","journal-title":"Pain Med (United States)"},{"issue":"5","key":"10.1016\/j.japh.2020.09.013_bib44","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.amepre.2018.01.034","article-title":"Trends in medical use of opioids in the U.S., 2006\u20132016","volume":"54","author":"Piper","year":"2018","journal-title":"Am J Prev Med"},{"issue":"2","key":"10.1016\/j.japh.2020.09.013_bib45","first-page":"119-122","article-title":"Analgesic utilization before and after rescheduling of hydrocodone in a large academic level 1 trauma center","volume":"12","author":"Schultz","year":"2016","journal-title":"J Opioid Manag"},{"issue":"3","key":"10.1016\/j.japh.2020.09.013_bib46","first-page":"268","article-title":"Change in prescription habits after federal rescheduling of hydrocodone combination products","volume":"29","author":"Seago","year":"2016","journal-title":"Proc (Bayl Univ Med Cent)"},{"issue":"2","key":"10.1016\/j.japh.2020.09.013_bib47","doi-asserted-by":"crossref","first-page":"E527","DOI":"10.1016\/j.ijrobp.2017.06.1866","article-title":"Impact of rescheduling hydrocodone combination products among cancer patients","volume":"99","author":"Shumway","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"10.1016\/j.japh.2020.09.013_bib48","doi-asserted-by":"crossref","first-page":"257","DOI":"10.5055\/jom.2018.0457","article-title":"Impact of rescheduling hydrocodone-combination products in an urban Texas county healthcare system","volume":"14","author":"Shumway","year":"2018","journal-title":"J Opioid Manag"},{"issue":"Supplement_2","key":"10.1016\/j.japh.2020.09.013_bib49","doi-asserted-by":"crossref","first-page":"S61","DOI":"10.1093\/ajhp\/zxy090","article-title":"Impact of hydrocodone reclassification on analgesic prescribing in the Veterans Health Administration","volume":"76","author":"Steckler","year":"2019","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.japh.2020.09.013_bib50","first-page":"S40","article-title":"Rescheduling hydrocodone was not associated with changing trends of prescribing by emergency physicians","volume":"26","author":"Weiner","year":"2019","journal-title":"Acad Emerg Med"},{"key":"10.1016\/j.japh.2020.09.013_bib51","first-page":"14","article-title":"Analysis of morphine milligram equivalents of opioids prescribed in a large urban safety net system","volume":"128","author":"Carroll","year":"2016","journal-title":"Postgrad Med"},{"issue":"5","key":"10.1016\/j.japh.2020.09.013_bib52","doi-asserted-by":"crossref","first-page":"317","DOI":"10.5055\/jom.2018.0464","article-title":"Prescribers' perceptions on the impact of hydrocodone rescheduling on geriatric pain management: a qualitative study","volume":"14","author":"Fernandez","year":"2018","journal-title":"J Opioid Manag"},{"issue":"2S","key":"10.1016\/j.japh.2020.09.013_bib53","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1016\/j.japh.2017.01.020","article-title":"Pharmacists' perceptions regarding the impact of hydrocodone rescheduling on prescription volume, workflow management, and patient outcomes","volume":"57","author":"Varisco","year":"2017","journal-title":"J Am Pharm Assoc (2003)"},{"issue":"4","key":"10.1016\/j.japh.2020.09.013_bib54","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.mcna.2008.03.005","article-title":"Acute liver failure including acetaminophen overdose","volume":"92","author":"Fontana","year":"2008","journal-title":"Med Clin North Am"},{"issue":"3","key":"10.1016\/j.japh.2020.09.013_bib55","doi-asserted-by":"crossref","first-page":"e190665","DOI":"10.1001\/jamanetworkopen.2019.0665","article-title":"Trends and patterns of geographic variation in opioid prescribing practices by state, United States, 2006\u20132017 [published correction appears in JAMA Netw Open. 2019;2(5):e194307]","volume":"2","author":"Schieber","year":"2019","journal-title":"JAMA Network Open"},{"issue":"3","key":"10.1016\/j.japh.2020.09.013_bib56","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.sapharm.2016.07.001","article-title":"Physicians' intention to prescribe hydrocodone combination products after rescheduling: a theory of reasoned action approach","volume":"13","author":"Fleming","year":"2017","journal-title":"Res Social Adm Pharm"},{"issue":"3","key":"10.1016\/j.japh.2020.09.013_bib57","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3390\/pharmacy3030129","article-title":"pharmacist opinions regarding the rescheduling of hydrocodone combination products: a pilot study","volume":"3","author":"Covvey","year":"2015","journal-title":"Pharmacy (Basel)"},{"issue":"9","key":"10.1016\/j.japh.2020.09.013_bib58","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1093\/pm\/pnv064","article-title":"An online survey of patients\u2019 experiences since the rescheduling of hydrocodone: the first 100 days","volume":"17","author":"Chambers","year":"2016","journal-title":"Pain Med"},{"issue":"7773","key":"10.1016\/j.japh.2020.09.013_bib59","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1038\/d41586-019-02687-1","article-title":"Treading the tightrope of opioid restrictions","volume":"573","author":"Eisenstein","year":"2019","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.japh.2020.09.013_bib60","doi-asserted-by":"crossref","first-page":"182","DOI":"10.2105\/AJPH.2017.304187","article-title":"Opioid crisis: no easy fix to its social and economic determinants","volume":"108","author":"Dasgupta","year":"2018","journal-title":"Am J Public Health"},{"issue":"11","key":"10.1016\/j.japh.2020.09.013_bib61","first-page":"866","article-title":"Does evidence support supervised injection sites?","volume":"63","author":"Ng","year":"2017","journal-title":"Can Fam Physician"},{"issue":"suppl 2","key":"10.1016\/j.japh.2020.09.013_bib62","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/add.13651","article-title":"Substance use outcomes of patients served by a large US implementation of Screening, Brief Intervention and Referral to Treatment (SBIRT)","volume":"112","author":"Aldridge","year":"2017","journal-title":"Addiction"},{"issue":"9","key":"10.1016\/j.japh.2020.09.013_bib63","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1377\/hlthaff.2019.00103","article-title":"Prescription Drug Monitoring Program mandates: impact on opioid prescribing and related hospital use","volume":"38","author":"Wen","year":"2019","journal-title":"Health Aff (Millwood)"},{"issue":"16","key":"10.1016\/j.japh.2020.09.013_bib64","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1056\/NEJMp1515917","article-title":"Reducing the risks of relief--the CDC opioid-prescribing guideline","volume":"374","author":"Frieden","year":"2016","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.japh.2020.09.013_bib66","doi-asserted-by":"crossref","first-page":"851","DOI":"10.7326\/M19-2797","article-title":"Comparative modeling to inform health policy decisions: a step forward","volume":"171","author":"Kim","year":"2019","journal-title":"Ann Intern Med"},{"issue":"10","key":"10.1016\/j.japh.2020.09.013_bib67","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.2105\/AJPH.2018.304590","article-title":"Modeling health benefits and harms of public policy responses to the US opioid epidemic","volume":"108","author":"Pitt","year":"2018","journal-title":"Am J Public Health"}],"container-title":["Journal of the American Pharmacists Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S154431912030474X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S154431912030474X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:48:05Z","timestamp":1761544085000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S154431912030474X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":66,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S154431912030474X"],"URL":"https:\/\/doi.org\/10.1016\/j.japh.2020.09.013","relation":{},"ISSN":["1544-3191"],"issn-type":[{"value":"1544-3191","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of hydrocodone rescheduling on opioid use outcomes: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Pharmacists Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.japh.2020.09.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Inc. on behalf of the American Pharmacists Association.","name":"copyright","label":"Copyright"}]}}